Jardiance vs Farxiga: Long-Term Durability of Blood Sugar Response

What Are Jardiance and Farxiga?

Jardiance (empagliflozin) and Farxiga (dapagliflozin) both belong to the SGLT2 inhibitor class. They block sodium-glucose cotransporter-2 in the proximal renal tubule, forcing the kidneys to excrete roughly 60 to 90 grams of glucose per day in the urine. That glucose loss produces a modest, sustained HbA1c reduction that does not depend on insulin secretion, which is exactly why durability differs from older agents like sulfonylureas.

Mechanism and Why Durability Differs From Other Drug Classes

Sulfonylureas drive insulin secretion and lose potency as beta-cell function declines. SGLT2 inhibitors act upstream of insulin entirely. Because the mechanism is renal rather than pancreatic, the glycemic effect tracks with kidney function rather than beta-cell reserve. Both empagliflozin and dapagliflozin maintain meaningful HbA1c reductions as long as eGFR stays above approximately 30 mL/min/1.73 m2 [1].

FDA-Approved Indications at a Glance

The FDA approved empagliflozin for type 2 diabetes glycemic control, reduction of cardiovascular death in adults with T2D and established cardiovascular disease, and heart failure (both HFrEF and HFpEF). Dapagliflozin carries approvals for T2D, heart failure with reduced ejection fraction (HFrEF, regardless of diabetes status), and chronic kidney disease [2]. That indication breadth matters when selecting an agent for a patient with multiple comorbidities.

Long-Term Glycemic Durability: What the Trial Data Show

Both drugs sustain HbA1c reductions for three to four years, with modest attenuation over time as expected from any glucose-lowering agent. Neither agent shows the sharp secondary failure pattern seen with sulfonylureas.

EMPA-REG OUTCOME: Empagliflozin's Landmark Durability Signal

EMPA-REG OUTCOME enrolled 7,020 adults with T2D and established cardiovascular disease and followed them for a median of 3.1 years [1]. The empagliflozin 10 mg and 25 mg arms both produced a mean HbA1c reduction of approximately 0.54 percentage points versus placebo at week 12, and that reduction was maintained with only minor attenuation through week 164. Critically, the trial was not designed as a glycemic durability study, but the sustained HbA1c separation through 164 weeks of follow-up provides strong real-world evidence that the glucose-lowering effect does not fade substantially across three-plus years [1].

The cardiovascular finding overshadowed glycemia in the original 2015 NEJM publication: a 38% relative reduction in cardiovascular death (3.7% vs 5.9%, hazard ratio 0.62, 95% CI 0.49 to 0.77, P<0.001) [1]. That mortality signal remains the most distinctive feature of empagliflozin's clinical profile.

DECLARE-TIMI 58 and DAPA-HF: Dapagliflozin's Evidence Base

DECLARE-TIMI 58 enrolled 17,160 patients with T2D and either established atherosclerotic cardiovascular disease or multiple cardiovascular risk factors [3]. Over a median 4.2-year follow-up, dapagliflozin produced sustained HbA1c reductions comparable to empagliflozin, with no significant difference in major adverse cardiovascular events versus placebo overall, though a significant reduction in hospitalization for heart failure was observed [3].

DAPA-HF then specifically enrolled 4,744 patients with HFrEF (ejection fraction <40%), of whom 45% did not have diabetes [4]. Dapagliflozin 10 mg reduced the composite of worsening heart failure or cardiovascular death by 26% relative to placebo (hazard ratio 0.74, 95% CI 0.65 to 0.85, P<0.001), an effect consistent across diabetic and non-diabetic subgroups [4]. This trial earned dapagliflozin its diabetes-independent HFrEF indication.

Head-to-Head Glycemic Comparison

No large randomized trial has directly compared empagliflozin against dapagliflozin for glycemic endpoints. Network meta-analyses consistently show overlapping confidence intervals for HbA1c reduction at standard doses. A 2019 network meta-analysis published in Diabetes Care (analyzing 112 trials, N=89,794) found that empagliflozin 10 mg and dapagliflozin 10 mg produced statistically indistinguishable HbA1c reductions of approximately 0.62 and 0.59 percentage points respectively versus placebo [5]. The difference of 0.03 percentage points falls well within the margin of measurement error for HbA1c assays.

Cardiovascular Outcomes: Where the Drugs Diverge

This is the most clinically meaningful area of difference between the two agents. Both reduce heart failure hospitalization. Only empagliflozin has demonstrated a statistically significant reduction in cardiovascular mortality in its outcomes trial.

Cardiovascular Mortality

EMPA-REG OUTCOME's 38% relative reduction in CV death (absolute risk reduction 2.2%) remains the clearest mortality signal in the SGLT2 class for T2D patients with established CVD [1]. DECLARE-TIMI 58 did not replicate a significant CV mortality reduction, likely reflecting its broader enrollment of patients without established CVD who carry lower baseline event rates [3].

The 2023 American Diabetes Association Standards of Care state: "For patients with type 2 diabetes and established cardiovascular disease, an SGLT2 inhibitor with demonstrated cardiovascular benefit should be prescribed" [6]. Empagliflozin is listed by name in that guidance given its EMPA-REG OUTCOME mortality data.

Heart Failure Hospitalization

Both drugs reduce hospitalization for heart failure. Dapagliflozin's DAPA-HF data extend its benefit to patients without diabetes, giving it an edge in the broader HFrEF population. Empagliflozin's EMPEROR-Reduced and EMPEROR-Preserved trials added HFrEF and HFpEF indications, making it the only SGLT2 inhibitor with FDA approval for both heart failure phenotypes [7].

The practical takeaway: for a patient with HFpEF and T2D, empagliflozin is currently the only SGLT2 inhibitor with a labeled HFpEF indication. For a patient with HFrEF without diabetes, dapagliflozin has been studied longest in that specific population.

Kidney Protection: EMPA-KIDNEY vs DAPA-CKD

Both agents now carry FDA approval for slowing CKD progression, supported by dedicated kidney outcome trials.

DAPA-CKD

DAPA-CKD enrolled 4,304 patients with CKD (eGFR 25 to 75 mL/min/1.73 m2) and urinary albumin-to-creatinine ratio >200 mg/g, 32% of whom did not have diabetes [8]. Dapagliflozin 10 mg reduced the primary composite of sustained >50% decline in eGFR, end-stage kidney disease, or death from renal or cardiovascular causes by 39% relative to placebo (hazard ratio 0.61, 95% CI 0.51 to 0.72, P<0.001) [8].

EMPA-KIDNEY

EMPA-KIDNEY enrolled 6,609 patients with a broader CKD spectrum (eGFR as low as 20 mL/min/1.73 m2), including patients with and without diabetes and with and without albuminuria [9]. Empagliflozin 10 mg reduced progression of kidney disease or cardiovascular death by 28% relative to placebo (hazard ratio 0.72, 95% CI 0.64 to 0.82, P<0.001) [9]. The trial enrolled lower-eGFR patients than DAPA-CKD, providing data in stage 4 CKD where fewer agents have evidence.

Both trials confirm class-level nephroprotection. Neither trial shows a statistically significant head-to-head superiority.

Glycemic Durability in Real-World Settings

Randomized trial populations are healthier than typical clinic patients. Real-world registry data fill that gap.

UK Biobank and CPRD Data

A 2022 analysis using the UK Clinical Practice Research Datalink (CPRD), covering 28,408 SGLT2 inhibitor initiators, found mean HbA1c reductions of 0.71 percentage points at 12 months that were sustained at 0.67 percentage points at 36 months across the class, with no statistically significant difference between empagliflozin and dapagliflozin subgroups [10]. Persistence was approximately 58% at 24 months for both agents, lower than trial protocol adherence but consistent with other oral antidiabetic classes.

Factors That Erode Glycemic Durability for Both Agents

Renal function is the main driver of attenuated SGLT2 inhibitor effect over time. As eGFR declines below 45 mL/min/1.73 m2, urinary glucose excretion drops and HbA1c lowering diminishes. Both drugs are generally not initiated for glycemic purposes when eGFR is below 30 mL/min/1.73 m2, though both can be continued for cardiorenal benefit at lower eGFR values. A patient whose eGFR drops from 75 to 38 mL/min/1.73 m2 over four years will see meaningful glycemic attenuation with either agent.

Weight gain, medication non-adherence, and disease progression all erode HbA1c control regardless of drug choice. Genital mycotic infections (occurring in roughly 5 to 6% of women and 2 to 3% of men) represent the most common reason patients discontinue both agents in real-world practice [10].

Safety Profiles: Similarities and Key Differences

The adverse-effect profiles of empagliflozin and dapagliflozin are essentially identical at the class level. Both carry boxed warnings for limb amputation risk in patients with peripheral artery disease (as a class concern following canagliflozin's CANVAS data), though neither empagliflozin nor dapagliflozin showed significant amputation signals in their own outcomes trials [1, 3].

Diabetic Ketoacidosis Risk

Both agents carry FDA warnings for euglycemic diabetic ketoacidosis (DKA), a condition where ketones accumulate even when blood glucose appears normal. Risk rises sharply during surgical fasting, severe illness, or very-low-carbohydrate diets. The FDA recommends holding both drugs at least three to four days before elective surgery [2]. Euglycemic DKA occurs at roughly 0.1 to 0.2 events per 100 patient-years with both agents.

Fournier's Gangrene

Both drugs carry an FDA warning for Fournier's gangrene (necrotizing fasciitis of the perineum), an extremely rare but life-threatening infection. The FDA identified 55 cases across the SGLT2 class through 2019 against a background rate making precise drug-specific incidence difficult to quantify, but the warning applies equally to both agents [2].

Volume Depletion

Starting either drug in patients already on loop diuretics, or in elderly patients with low body weight, risks symptomatic hypotension. Dapagliflozin's DAPA-HF protocol explicitly recommended assessing volume status before initiation in heart failure patients [4]. The same caution applies to empagliflozin in EMPEROR-Reduced.

Should You Switch from Jardiance to Farxiga?

Switching is pharmacologically straightforward. Both agents work through the same transporter, have similar half-lives (approximately 12 hours for empagliflozin, approximately 12.9 hours for dapagliflozin), and do not require a washout period. You can switch on the same day.

Clinical Reasons to Switch

The most evidence-backed reasons to switch are indication-driven rather than glycemia-driven. Switching from empagliflozin to dapagliflozin makes sense if a patient develops HFrEF without diabetes and the prescriber wants to use a drug with a diabetes-independent FDA label for that indication. It may also be cost-driven: formulary positioning varies by insurance plan, and dapagliflozin may carry lower out-of-pocket costs on some commercial formularies.

Switching from dapagliflozin to empagliflozin makes sense for a patient with established CVD where the prescriber wants the specific CV mortality reduction demonstrated in EMPA-REG OUTCOME, or for a patient with HFpEF where empagliflozin holds the only labeled indication.

What Does Not Change After Switching

Blood glucose control will be essentially unchanged within two to four weeks after a same-dose-class switch. Expect no HbA1c change beyond the normal biological variability of 0.2 to 0.3 percentage points between measurements. Adverse-effect profile, monitoring requirements, and lifestyle counseling (adequate hydration, genital hygiene) remain identical.

Practical Switching Protocol

Stop the current agent on day one. Start the new agent at its standard starting dose (empagliflozin 10 mg or dapagliflozin 10 mg) on day one. Recheck HbA1c at 12 weeks to confirm glycemic continuity. No dose adjustment to concurrent metformin, GLP-1 agonists, or basal insulin is required at the time of the switch, though providers may reassess the full regimen during the switch visit.

Dosing Reference Table

| Feature | Jardiance (empagliflozin) | Farxiga (dapagliflozin) | |---|---|---| | Starting dose | 10 mg once daily | 5 or 10 mg once daily | | Maximum dose | 25 mg once daily | 10 mg once daily | | HbA1c reduction | ~0.62 pp at 10 mg | ~0.59 pp at 10 mg | | CV mortality reduction | Yes (EMPA-REG OUTCOME) | Not demonstrated | | HFrEF approval | Yes (EMPEROR-Reduced) | Yes (DAPA-HF) | | HFpEF approval | Yes (EMPEROR-Preserved) | No | | CKD approval | Yes (EMPA-KIDNEY) | Yes (DAPA-CKD) | | Washout needed to switch | No | No |

Prescribing Considerations by Patient Profile

Not every patient with T2D fits the same profile. The glycemic durability data are nearly identical. The outcomes data are not.

Patient With T2D and Established Atherosclerotic CVD

EMPA-REG OUTCOME's mortality reduction gives empagliflozin a clinical edge for this subgroup. The 2023 ADA Standards of Care and the 2021 ESC diabetes guidelines both place agents with demonstrated CV mortality reduction at the top of the hierarchy for patients who already have CVD [6].

Patient With T2D and HFrEF

Either agent is appropriate. Dapagliflozin's DAPA-HF data are the most cited in this indication because DAPA-HF was the first large HFrEF trial for the class. Empagliflozin's EMPEROR-Reduced showed a similar hazard ratio of 0.75 (95% CI 0.65 to 0.86) [7]. Both options carry strong guideline support.

Patient With CKD and No Diabetes

Dapagliflozin's DAPA-CKD enrolled a large non-diabetic CKD cohort and is FDA-approved for this indication. Empagliflozin's EMPA-KIDNEY also enrolled non-diabetic patients, but the FDA CKD label came after DAPA-CKD. Either agent works; local formulary access often determines the choice.

Patient With T2D and eGFR 20 to 30 mL/min/1.73 m2

For glycemia alone, neither agent is useful at this eGFR range. For cardiorenal protection, empagliflozin's EMPA-KIDNEY included patients down to eGFR 20 mL/min/1.73 m2, providing some of the lowest-eGFR data in the class [9]. This does not make empagliflozin definitively superior here, but it does mean there is more specific trial evidence for its use at that eGFR level.